Generation of induced pluripotent stem (iPS) cells derived from a murine model of Pompe disease and differentiation of Pompe-iPS cells into skeletal muscle cells

Molecular Genetics and Metabolism

Volumn 104, Issue 1-2, 2011, Pages 123-128

  Kawagoe, Shiho ^a   Higuchi, Takashi ^a   Meng, Xing Li ^b   Shimada, Yohta ^a   Shimizu, Hiromi ^a   Hirayama, Reimi ^a   Fukuda, Takahiro ^a   Chang, Hsi ^c   Nakahata, Tatsutoshi ^d   Fukada, So Ichiro ^e   Ida, Hiroyuki ^a   Kobayashi, Hiroshi ^a   Ohashi, Toya ^a   Eto, Yoshikastu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d KYOTO UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

Acid glucosidase; Induced pluripotent stem (iPS); Pompe disease; Reprogramming factor; Skeletal muscle

Indexed keywords

ACID PHOSPHATASE; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLYCOGEN; KRUPPEL LIKE FACTOR 4; MATRIGEL; MYOSIN HEAVY CHAIN; OCTAMER TRANSCRIPTION FACTOR 4; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR SOX2;

A BAND; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL STRUCTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; GENETIC TRANSFECTION; GLYCOGEN STORAGE DISEASE TYPE 2; H BAND; I BAND; KNOCKOUT MOUSE; LYSOSOME; MALE; MOUSE; MUSCLE CELL; MUSCLE Z BAND; NONHUMAN; PERIODIC ACID SCHIFF STAIN; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SKELETAL MUSCLE; SPINDLE CELL; STAINING; TERATOMA; WILD TYPE;

ANIMALS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL SHAPE; DISEASE MODELS, ANIMAL; GLYCOGEN STORAGE DISEASE TYPE II; INDUCED PLURIPOTENT STEM CELLS; MICE; MICE, NUDE; MUSCLE CELLS; MUSCLE, SKELETAL; PHENOTYPE;

IPS; MURINAE; MUS;

EID: 80052531213     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.05.020     Document Type: Article

References (28)

1. Hirschhorn R., Reuser A. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. The Metabolic and Molecular Bases of Inherited Disease 2001, 3389-3420. McGraw-Hill, New York. C. Scriver, A. Beaudet, W. Sly, D. Valle (Eds.).
2. Kroos M.A., Pomponio R.J., Hagemans M.L., Keulemans J.L., Phipps M., DeRiso M., Palmer R.E., Ausems M.G., Van der Beek N.A., Van Diggelen O.P., Halley D.J., Van der Ploeg A.T., Reuser A.J. Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype. Neurology 2007, 68:110-115.
3. Hagemans M.L., Winkel L.P., Van Doorn P.A., Hop W.J., Loonen M.C., Reuser A.J., Van der Ploeg A.T. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005, 128:671-677.
4. Kishnani P.S., Corzo D., Nicolino M., Byrne B., Mandel H., Hwu W.L., Leslie N., Levine J., Spencer C., McDonald M., Li J., Dumontier J., Halberthal M., Chien Y.H., Hopkin R., Vijayaraghavan S., Gruskin D., Bartholomew D., van der Ploeg A.., Clancy J.P., Parini R., Morin G., Beck M., De la Gastine G.S., Jokic M., Thurberg B., Richards S., Bali D., Davison M., Worden M.A., Chen Y.T., Wraith J.E. Recombinant human acid α-gluco-sidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007, 68:99-109.
5. Nicolino M., Byrne B., Wraith J.E., Leslie N., Mandel H., Freyer D.R., Pivnick G.L., Arnold E.K., Ottinger C.J., Robinson P.H., Loo J.C., Smitka M., Jardine P., Tatò L., Chabrol B., McCandless S., Kimura S., Mehta L., Bali D., Skrinar A., Morgan C., Rangachari L., Corzo D., Kishnani P.S. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet. Med. 2009, 11:210-219.
6. Kishnani P.S., Corzo D., Leslie N.D., Gruskin D., Van der Ploeg A., Clancy J.P., Parini R., Morin G., Beck M., Bauer M.S., Jokic M., Tsai C.E., Tsai B.W., Morgan C., O'Meara T., Richards S., Tsao E.C., Mandel H. Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease. Pediatr. Res. 2009, 66:329-355.
7. Angelini C., Semplicini C., Tonin P., Filosto M., Pegoraro E., Sorarù G., Fanin M. Progress in enzyme replacement therapy in glycogen storage disease type II. Ther. Adv. Neurol. Disord. 2009, 2:143-153.
8. Strothotte S., Strigl-Pill N., Grunert B., Kornblum C., Eger K., Wessig C., Deschauer M., Breunig F., Glocker F.X., Vielhaber S., Brejova A., Hilz M., Reiners K., Müller-Felber W., Mengel E., Spranger M., Schoser B. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J. Neurol. 2009, 257:91-97.
9. van der Ploeg A.T., Clemens P.R., Corzo D., Escolar D.M., Florence J., Groeneveld G.J., Herson S., Kishnani P.S., Laforet P., Lake S.L., Lange D.J., Leshner R.T., Mayhew J.E., Morgan C., Nozaki K., Park D.J., Pestronk A., Rosenbloom B., Skrinar A., van Capelle C.I., van der Beek N.A., Wasserstein M., Zivkovic S.A. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med. 2010, 362. 1396-406.
10. Wang J., Lozier J., Johnson G., Kirshner S., Verthelyi D., Pariser A., Shores E., Rosenberg A. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat. Biotechnol. 2008, 26:901-908.
11. Kobayashi H., Shimada Y., Ikegami M., Kawai T., Sakurai K., Urashima T., Ijima M., Fujiwara M., Kaneshiro E., Ohashi T., Eto Y., Ishigaki K., Osawa M., Kyosen S., Ida H. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case. Mol. Genet. Metab. 2010, 100:14-19.
12. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
13. Mizuno Y., Chang H., Umeda K., Niwa A., Iwasa T., Awaya T., Fukada S., Yamamoto H., Yamanaka S., Nakahata T., Heike T. Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells. FASEB J. 2010, 24:2245-2253.
14. Chang H., Yoshimoto M., Umeda K., Iwasa T., Mizuno Y., Fukada S., Yamamoto H., Motohashi N., Miyagoe-Suzuki Y., Takeda S., Heike T., Nakahata T. Generation of transplantable, functional satellite-like cells from mouse embryonic stem cells. FASEB J. 2009, 23:1907-1919.
15. Nakagawa M., Koyanagi M., Tanabe K., Takahashi K., Ichisaka T., Aoi T., Okita K., Mochiduki Y., Takizawa N., Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 2008, 26:101-106.
16. Meng X.L., Shen J.S., Kawagoe S., Ohashi T., Brady R.O., Eto Y. Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders. PNAS 2010, 107:7886-7891.
17. Yamanaka S., Takahashi K. Induction of pluripotent stem cells from fibroblast cultures. Nat. Protoc. 2007, 2:3081-3089.
18. Meikle P.J., Hopwood J.J., Clague A.E., Carey W.F. Prevalence of lysosomal storage disorders. JAMA 1999, 281:249-254.
19. Kyosen S.O., Iizuka S., Kobayashi H., Kimura T., Fukuda T., Shen J., Shimada Y., Ida H., Eto Y., Ohashi T. Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction. Gene Ther. 2010, 17:521-530.
20. Mcadams A.J., Wilson H.E. The liver in generalized glycogen storage disease: light microscopic observations. Am. J. Pathol. 1966, 49:99-111.
21. Badoual J., Lestradet H., Vilde J.I. Une forme atypique de glycogenose par deficit en maltase acid. Sem. Hôp. Paris 1967, 43:1427-1434.
22. H.G. Hers, and T. de Barsy, Type II Glycogenosis: Acid Maltase Deficiency, Lysosomes and Storage Diseases. (1973) 197-216.
23. Fukuda T., Ewan L., Bauer M., Mattaliano R.J., Zaal K., Ralston E., Plotz P.H., Raben N. Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann. Neurol. 2006, 59:700-708.
24. Raben N., Takikita S., Pittis M.G., Bembi B., Marie S.K.N., Roberts A., Page L., Kishnani P.S., Schoser B.G.H., Chien Y.H., Ralston E., Nagaraju K., Plotz P.H. Deconstructing Pompe disease by analyzing single muscle fibers. Autophagy 2007, 3:546-552.
25. Fukuda T., Ahearn M., Roberts A., Mattaliano R.J., Zaal K., Ralston E., Plotz P.H., Raben N. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol. Ther. 2006, 14:831-839.
26. Raben N., Ralston E., Chien Y.H., Baum R., Schreiner C., Hwu W.L., Zaal K.J., Plotz P.H. Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy. Mol. Genet. Metab. 2010, 101:324-331.
27. Sun B., Young S.P., Li P., Di C., Brown T., Salva M.Z., Li S., Bird A., Yan Z., Auten R., Hauschka S.D., Koeberl D.D. Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy. Mol. Ther. 2008, 16:1366-1371.
28. Morita S., Kojima T., Kitamura T., Plat E. An efficient and stable system for transient packaging of retroviruses. Gene Ther. 2007, 7:1063-1066.